Home Neurogastrx

Neurogastrx

In operation
Series B
Gastrointestinal Disease Therapeutics Developer
Basic
Enterprise Profile

Basic Information

Neurogastrx is a developer of gastrointestinal disease therapeutics, with its product NG101 being a potent and selective peripheral nerve-targeted dopamine D2/D3 receptor antagonist. It is primarily used for symptoms such as gastroparesis and aims to improve the treatment of refractory gastrointestinal conditions by targeting the enteric nervous system.
Neurogastrx, Inc.
Massachusetts,United States of America
15~50 people
January 01, 2012
info@neurogastrx.com

Enterprise Profile

Industrial Sector
New Drug Development Manufacture of Biological Pharmaceutical Products
Concept
Digestive System Diseases Therapeutic Products
Application Scenarios
Biologics Innovative Drugs